Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Clinical outcomes of endoscopic balloon dilatation of intestinal strictures in patients with Crohn's disease.

Winder O, Fliss-Isakov N, Winder G, Scapa E, Yanai H, Barnes S, Dekel R, Dotan I, Maharshak N.

Medicine (Baltimore). 2019 Aug;98(35):e16864. doi: 10.1097/MD.0000000000016864.

2.

Dietary iron variably modulates assembly of the intestinal microbiota in colitis-resistant and colitis-susceptible mice.

Ellermann M, Gharaibeh RZ, Maharshak N, Peréz-Chanona E, Jobin C, Carroll IM, Arthur JC, Plevy SE, Fodor AA, Brouwer CR, Sartor RB.

Gut Microbes. 2019 Jun 10:1-19. doi: 10.1080/19490976.2019.1599794. [Epub ahead of print]

PMID:
31179826
3.

Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls.

Shapiro J, Cohen NA, Shalev V, Uzan A, Koren O, Maharshak N.

J Dermatol. 2019 Jul;46(7):595-603. doi: 10.1111/1346-8138.14933. Epub 2019 May 29.

PMID:
31141234
4.

Fecal Proteases from Pouchitis Patients Activate Protease Activating Receptor-2 to Disrupt the Epithelial Barrier.

Hoffman S, Cohen NA, Carroll IM, Tulchinsky H, Borovok I, Dotan I, Maharshak N.

J Crohns Colitis. 2019 May 6. pii: jjz086. doi: 10.1093/ecco-jcc/jjz086. [Epub ahead of print]

PMID:
31056700
5.

Fruit Consumption is Associated with Alterations in Microbial Composition and Lower Rates of Pouchitis.

Godny L, Maharshak N, Reshef L, Goren I, Yahav L, Fliss-Isakov N, Gophna U, Tulchinsky H, Dotan I.

J Crohns Colitis. 2019 Sep 27;13(10):1265-1272. doi: 10.1093/ecco-jcc/jjz053.

PMID:
30828722
6.

A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial.

Huttner BD, de Lastours V, Wassenberg M, Maharshak N, Mauris A, Galperine T, Zanichelli V, Kapel N, Bellanger A, Olearo F, Duval X, Armand-Lefevre L, Carmeli Y, Bonten M, Fantin B, Harbarth S; R-Gnosis WP3 study group.

Clin Microbiol Infect. 2019 Jul;25(7):830-838. doi: 10.1016/j.cmi.2018.12.009. Epub 2019 Jan 4.

7.

Five years of fecal microbiota transplantation - an update of the Israeli experience.

Greenberg SA, Youngster I, Cohen NA, Livovsky DM, Strahilevitz J, Israeli E, Melzer E, Paz K, Fliss-Isakov N, Maharshak N.

World J Gastroenterol. 2018 Dec 21;24(47):5403-5414. doi: 10.3748/wjg.v24.i47.5403.

8.

Impaired COMMD10-Mediated Regulation of Ly6Chi Monocyte-Driven Inflammation Disrupts Gut Barrier Function.

Mouhadeb O, Ben Shlomo S, Cohen K, Farkash I, Gruber S, Maharshak N, Halpern Z, Burstein E, Gluck N, Varol C.

Front Immunol. 2018 Nov 14;9:2623. doi: 10.3389/fimmu.2018.02623. eCollection 2018.

9.

Serum cholinesterase activity is elevated in female diarrhea-predominant irritable bowel syndrome patients compared to matched controls.

Hod K, Sperber AD, Maharshak N, Ron Y, Shapira I, David Z, Rogowski O, Berliner S, Shenhar-Tsarfaty S, Dekel R.

Neurogastroenterol Motil. 2018 Dec;30(12):e13464. doi: 10.1111/nmo.13464. Epub 2018 Sep 21.

PMID:
30240124
10.

Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT.

Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S, Zur M, Regev-Lehavi D, Ben-Zeev Brik R, Federici S, Horn M, Cohen Y, Moor AE, Zeevi D, Korem T, Kotler E, Harmelin A, Itzkovitz S, Maharshak N, Shibolet O, Pevsner-Fischer M, Shapiro H, Sharon I, Halpern Z, Segal E, Elinav E.

Cell. 2018 Sep 6;174(6):1406-1423.e16. doi: 10.1016/j.cell.2018.08.047.

11.

Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features.

Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, Kotler E, Zur M, Regev-Lehavi D, Brik RB, Federici S, Cohen Y, Linevsky R, Rothschild D, Moor AE, Ben-Moshe S, Harmelin A, Itzkovitz S, Maharshak N, Shibolet O, Shapiro H, Pevsner-Fischer M, Sharon I, Halpern Z, Segal E, Elinav E.

Cell. 2018 Sep 6;174(6):1388-1405.e21. doi: 10.1016/j.cell.2018.08.041.

12.

Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience.

Kopylov U, Avni-Biron I, Ron Y, Koslowsky B, Waterman M, Daher S, Ungar B, Schwartz D, Zittan E, Openhaim M, Yanai H, Maharshak N, Bar Gil Shitrit A, Naftali T, Eliakim R, Chowers Y, Ben-Horin S, Dotan I.

Dig Liver Dis. 2019 Jan;51(1):68-74. doi: 10.1016/j.dld.2018.07.040. Epub 2018 Aug 10.

PMID:
30172649
13.

The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome.

Hod K, Dekel R, Aviv Cohen N, Sperber A, Ron Y, Boaz M, Berliner S, Maharshak N.

Neurogastroenterol Motil. 2018 Dec;30(12):e13456. doi: 10.1111/nmo.13456. Epub 2018 Aug 23.

PMID:
30136337
14.

Clostridium difficile fecal toxin level is associated with disease severity and prognosis.

Cohen NA, Miller T, Na'aminh W, Hod K, Adler A, Cohen D, Guzner-Gur H, Santo E, Halpern Z, Carmeli Y, Maharshak N.

United European Gastroenterol J. 2018 Jun;6(5):773-780. doi: 10.1177/2050640617750809. Epub 2017 Dec 21.

15.

Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.

Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M.

Inflamm Bowel Dis. 2018 Oct 12;24(11):2442-2451. doi: 10.1093/ibd/izy155.

PMID:
29788318
16.

Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.

Maharshak N, Ringel Y, Katibian D, Lundqvist A, Sartor RB, Carroll IM, Ringel-Kulka T.

Dig Dis Sci. 2018 Jul;63(7):1890-1899. doi: 10.1007/s10620-018-5086-4. Epub 2018 May 17.

PMID:
29777439
17.

Crohn's Disease Behavior and Location is Altered when Associated with Primary Sclerosing Cholangitis.

Iny O, Yanai H, Matalon S, Santo E, Shibolet O, Dotan I, Maharshak N.

Isr Med Assoc J. 2018 Jan;20(1):25-29.

18.

Clostridium difficile infection in hospitalized patients with inflammatory bowel disease: Prevalence, risk factors, and prognosis.

Maharshak N, Barzilay I, Zinger H, Hod K, Dotan I.

Medicine (Baltimore). 2018 Feb;97(5):e9772. doi: 10.1097/MD.0000000000009772. Erratum in: Medicine (Baltimore). 2018 Feb;97(8):e0023.

19.

Of mice and men: a novel dietary supplement for the treatment of ulcerative colitis.

Shapira S, Leshno A, Katz D, Maharshak N, Hevroni G, Jean-David M, Kraus S, Galazan L, Aroch I, Kazanov D, Hallack A, Becker S, Umanski M, Moshkowitz M, Dotan I, Arber N.

Therap Adv Gastroenterol. 2017 Nov 28;11:1756283X17741864. doi: 10.1177/1756283X17741864. eCollection 2018.

20.

Fecal Transplantation for Treatment of Clostridium Difficile Infection in Elderly and Debilitated Patients.

Friedman-Korn T, Livovsky DM, Maharshak N, Aviv Cohen N, Paz K, Bar-Gil Shitrit A, Goldin E, Koslowsky B.

Dig Dis Sci. 2018 Jan;63(1):198-203. doi: 10.1007/s10620-017-4833-2. Epub 2017 Nov 13.

PMID:
29134299
21.

Corrigendum: NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth.

Chen L, Wilson JE, Koenigsknecht MJ, Chou WC, Montgomery SA, Truax AD, Brickey WJ, Packey CD, Maharshak N, Matsushima GK, Plevy SE, Young VB, Sartor RB, Ting JP.

Nat Immunol. 2017 Oct 18;18(11):1270. doi: 10.1038/ni1117-1270b.

PMID:
29044233
22.

Erratum: NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth.

Chen L, Wilson JE, Koenigsknecht MJ, Chou WC, Montgomery SA, Truax AD, Brickey WJ, Packey CD, Maharshak N, Matsushima GK, Plevy SE, Young VB, Sartor RB, Ting JP.

Nat Immunol. 2017 Jul 19;18(8):951. doi: 10.1038/ni0817-951e. No abstract available.

PMID:
28722719
23.

A Retrospective Comparison of Fecal Microbial Transplantation Methods for Recurrent Clostridium Difficile Infection.

Cohen NA, Livovsky DM, Yaakobovitch S, Ben Yehoyada M, Ben Ami R, Adler A, Guzner-Gur H, Goldin E, Santo ME, Halpern Z, Paz K, Maharshak N.

Isr Med Assoc J. 2016 Oct;18(10):594-599.

24.

Novel Indications for Fecal Microbial Transplantation: Update and Review of the Literature.

Cohen NA, Maharshak N.

Dig Dis Sci. 2017 May;62(5):1131-1145. doi: 10.1007/s10620-017-4535-9. Epub 2017 Mar 17. Review.

PMID:
28315032
25.

NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth.

Chen L, Wilson JE, Koenigsknecht MJ, Chou WC, Montgomery SA, Truax AD, Brickey WJ, Packey CD, Maharshak N, Matsushima GK, Plevy SE, Young VB, Sartor RB, Ting JP.

Nat Immunol. 2017 May;18(5):541-551. doi: 10.1038/ni.3690. Epub 2017 Mar 13. Erratum in: Nat Immunol. 2017 Jul 19;18(8):951. Erratum in: Nat Immunol. 2017 Oct 18;18(11):1270.

26.

A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS.

Hod K, Sperber AD, Ron Y, Boaz M, Dickman R, Berliner S, Halpern Z, Maharshak N, Dekel R.

Neurogastroenterol Motil. 2017 Jul;29(7). doi: 10.1111/nmo.13037. Epub 2017 Mar 8.

PMID:
28271623
27.

Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.

Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S, Ungar B, Yanai H, Maharshak N, Ben-Bassat O, Lichtenstein L, Bar-Gil Shitrit A, Israeli E, Schwartz D, Zittan E, Eliakim R, Chowers Y, Ben-Horin S, Dotan I.

Inflamm Bowel Dis. 2017 Mar;23(3):404-408. doi: 10.1097/MIB.0000000000001039.

PMID:
28178003
28.

Alterations of Enteric Microbiota in Patients with a Normal Ileal Pouch Are Predictive of Pouchitis.

Maharshak N, Cohen NA, Reshef L, Tulchinsky H, Gophna U, Dotan I.

J Crohns Colitis. 2017 Mar 1;11(3):314-320. doi: 10.1093/ecco-jcc/jjw157.

PMID:
27613294
29.

CD151 Regulates T-Cell Migration in Health and Inflammatory Bowel Disease.

Zelman-Toister E, Bakos E, Cohen S, Zigmond E, Shezen E, Grabovsky V, Sagiv A, Hart G, Kaushansky N, Ben-Nun A, Maharshak N, Sonnenberg A, Alon R, Becker-Herman S, Shachar I.

Inflamm Bowel Dis. 2016 Feb;22(2):257-67. doi: 10.1097/MIB.0000000000000621.

PMID:
26529559
30.

The APC I1307K allele conveys a significant increased risk for cancer.

Leshno A, Shapira S, Liberman E, Kraus S, Sror M, Harlap-Gat A, Avivi D, Galazan L, David M, Maharshak N, Moanis S, Arber N, Moshkowitz M.

Int J Cancer. 2016 Mar 15;138(6):1361-7. doi: 10.1002/ijc.29876. Epub 2015 Oct 13.

31.

Fecal Microbiota Transplantation for Clostridium difficile-Associated Diarrhea.

Cohen NA, Ben Ami R, Guzner-Gur H, Santo ME, Halpern Z, Maharshak N.

Isr Med Assoc J. 2015 Aug;17(8):510-4. Review.

32.

Escherichia coli heme oxygenase modulates host innate immune responses.

Maharshak N, Ryu HS, Fan TJ, Onyiah JC, Schulz S, Otterbein SL, Wong R, Hansen JJ, Otterbein LE, Carroll IM, Plevy SE.

Microbiol Immunol. 2015 Aug;59(8):452-65. doi: 10.1111/1348-0421.12282.

33.

Pouch Inflammation Is Associated With a Decrease in Specific Bacterial Taxa.

Reshef L, Kovacs A, Ofer A, Yahav L, Maharshak N, Keren N, Konikoff FM, Tulchinsky H, Gophna U, Dotan I.

Gastroenterology. 2015 Sep;149(3):718-27. doi: 10.1053/j.gastro.2015.05.041. Epub 2015 May 27.

PMID:
26026389
34.

[Use of fecal microbial transplantations for disease states in Israel].

Maharshak N.

Harefuah. 2015 Mar;154(3):152-4, 213. Hebrew.

PMID:
25962241
35.

High-sensitive C-Reactive Protein as a Marker for Inflammation in Irritable Bowel Syndrome.

Hod K, Ringel-Kulka T, Martin CF, Maharshak N, Ringel Y.

J Clin Gastroenterol. 2016 Mar;50(3):227-32. doi: 10.1097/MCG.0000000000000327.

36.

Enterococcus faecalis Gelatinase Mediates Intestinal Permeability via Protease-Activated Receptor 2.

Maharshak N, Huh EY, Paiboonrungruang C, Shanahan M, Thurlow L, Herzog J, Djukic Z, Orlando R, Pawlinski R, Ellermann M, Borst L, Patel S, Dotan I, Sartor RB, Carroll IM.

Infect Immun. 2015 Jul;83(7):2762-70. doi: 10.1128/IAI.00425-15. Epub 2015 Apr 27.

37.

High throughput sequencing reveals distinct microbial populations within the mucosal and luminal niches in healthy individuals.

Ringel Y, Maharshak N, Ringel-Kulka T, Wolber EA, Sartor RB, Carroll IM.

Gut Microbes. 2015;6(3):173-81. doi: 10.1080/19490976.2015.1044711.

38.

Heme oxygenase-1 and carbon monoxide regulate intestinal homeostasis and mucosal immune responses to the enteric microbiota.

Onyiah JC, Sheikh SZ, Maharshak N, Otterbein LE, Plevy SE.

Gut Microbes. 2014 Mar-Apr;5(2):220-4. doi: 10.4161/gmic.27290. Epub 2013 Dec 20. Review.

39.

NFIL3-deficient mice develop microbiota-dependent, IL-12/23-driven spontaneous colitis.

Kobayashi T, Steinbach EC, Russo SM, Matsuoka K, Nochi T, Maharshak N, Borst LB, Hostager B, Garcia-Martinez JV, Rothman PB, Kashiwada M, Sheikh SZ, Murray PJ, Plevy SE.

J Immunol. 2014 Feb 15;192(4):1918-27. doi: 10.4049/jimmunol.1301819. Epub 2014 Jan 17.

40.

Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications.

Carroll IM, Maharshak N.

World J Gastroenterol. 2013;19(43):7531-43. doi: 10.3748/wjg.v19.i43.7531. Review.

41.

Chloride channel ClC-2 is a key factor in the development of DSS-induced murine colitis.

Nighot P, Young K, Nighot M, Rawat M, Sung EJ, Maharshak N, Plevy SE, Ma T, Blikslager A.

Inflamm Bowel Dis. 2013 Dec;19(13):2867-77. doi: 10.1097/MIB.0b013e3182a82ae9.

42.

Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome.

Ringel Y, Maharshak N.

Am J Physiol Gastrointest Liver Physiol. 2013 Oct 15;305(8):G529-41. doi: 10.1152/ajpgi.00207.2012. Epub 2013 Jul 25. Review.

43.

Altered enteric microbiota ecology in interleukin 10-deficient mice during development and progression of intestinal inflammation.

Maharshak N, Packey CD, Ellermann M, Manick S, Siddle JP, Huh EY, Plevy S, Sartor RB, Carroll IM.

Gut Microbes. 2013 Jul-Aug;4(4):316-24. doi: 10.4161/gmic.25486. Epub 2013 Jun 20.

44.

MicroRNA-132 modulates cholinergic signaling and inflammation in human inflammatory bowel disease.

Maharshak N, Shenhar-Tsarfaty S, Aroyo N, Orpaz N, Guberman I, Canaani J, Halpern Z, Dotan I, Berliner S, Soreq H.

Inflamm Bowel Dis. 2013 Jun;19(7):1346-53. doi: 10.1097/MIB.0b013e318281f47d.

PMID:
23598815
45.

Oesophageal involvement in bullous pemphigoid.

Maharshak N, Sagi M, Santos E, Sprecher E, Goldberg I.

Clin Exp Dermatol. 2013 Apr;38(3):274-5. doi: 10.1111/j.1365-2230.2012.04408.x.

PMID:
23517357
46.

Early life stress triggers persistent colonic barrier dysfunction and exacerbates colitis in adult IL-10-/- mice.

Lennon EM, Maharshak N, Elloumi H, Borst L, Plevy SE, Moeser AJ.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):712-9. doi: 10.1097/MIB.0b013e3182802a4e.

47.

Carbon monoxide and heme oxygenase-1 prevent intestinal inflammation in mice by promoting bacterial clearance.

Onyiah JC, Sheikh SZ, Maharshak N, Steinbach EC, Russo SM, Kobayashi T, Mackey LC, Hansen JJ, Moeser AJ, Rawls JF, Borst LB, Otterbein LE, Plevy SE.

Gastroenterology. 2013 Apr;144(4):789-98. doi: 10.1053/j.gastro.2012.12.025. Epub 2012 Dec 22.

48.

A cell permeable peptide inhibitor of NFAT inhibits macrophage cytokine expression and ameliorates experimental colitis.

Elloumi HZ, Maharshak N, Rao KN, Kobayashi T, Ryu HS, Mühlbauer M, Li F, Jobin C, Plevy SE.

PLoS One. 2012;7(3):e34172. doi: 10.1371/journal.pone.0034172. Epub 2012 Mar 27.

49.

Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation.

Maharshak N, Halfon P, Deutsch V, Peretz H, Berliner S, Fishman S, Zelber-Sagi S, Rozovski U, Leshno M, Oren R.

World J Gastroenterol. 2011 Dec 7;17(45):5007-13. doi: 10.3748/wjg.v17.i45.5007.

50.

The cytokine midkine and its receptor RPTPζ regulate B cell survival in a pathway induced by CD74.

Cohen S, Shoshana OY, Zelman-Toister E, Maharshak N, Binsky-Ehrenreich I, Gordin M, Hazan-Halevy I, Herishanu Y, Shvidel L, Haran M, Leng L, Bucala R, Harroch S, Shachar I.

J Immunol. 2012 Jan 1;188(1):259-69. doi: 10.4049/jimmunol.1101468. Epub 2011 Dec 2.

Supplemental Content

Loading ...
Support Center